A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 28 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 28 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
- 07 Jun 2016 Results of dose exploration phase of the study (n=9) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology